This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cold-EEZE® Announces Launch Of NEW Cold-EEZE® Oral Spray





DOYLESTOWN, Pa., Nov. 1, 2011 /PRNewswire/ -- ProPhase Labs (NASDAQ: PRPH), makers of Cold-EEZE, a leader in over-the-counter (OTC) homeopathic cold remedies, continues to pioneer the category as they launch their first-ever Cold-EEZE Oral Spray.  The new Oral Spray is formulated with zinc gluconate, the same effective active ingredient found in the best-selling, clinically proven and #1 pharmacist recommended Cold-EEZE lozenges. 

(Photo: http://photos.prnewswire.com/prnh/20111101/NY96632 )

The effective proprietary formula reduces the severity and duration of the common cold. Two sprays offer the same amount of cold remedy (active ingredient zinc gluconate) as one Cold-EEZE lozenge.  The recommended two sprays per usage offer 13.3 mg of zinc gluconate and the bottle contains at least 45 doses (90 sprays). The new Oral Spray is available in a convenient, easy to carry spray bottle and is available in cherry and mint flavors.

"Our Cold-EEZE Oral Spray is a new opportunity to provide relief to our consumers in a new delivery system," says Ted Karkus, Chairman and Chief Executive Officer of ProPhase Labs. "Our lozenges have always been a leader in the over-the-counter cough & cold category and we saw Cold-EEZE Oral Spray as the logical next step in offering our consumers variety and alternatives to the traditional lozenge to help them reduce the severity and duration of their colds."

For best results, the Cold-EEZE Oral Spray should be taken at the onset of symptoms. Consumers spray twice in the mouth on the inside of cheeks, roof of mouth and gums. Retain for 15 seconds and then swallow. Repeat every two to four hours (up to 12 sprays/6 doses per day) as needed until symptoms subside. 

For more information, visit http://www.coldeeze.com.

About ProPhase Labs

ProPhase Labs (NASDAQ: PRPH) is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE ® cold remedy family of lozenges clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE ® customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. Cold-EEZE Oral Spray is available at many major chain drug, mass and grocery retailers nation-wide.

ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE ® lozenges and fulfill other contract manufacturing opportunities.  ProPhase also owns 50% of Phusion Laboratories, LLC ("Phusion"). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds.  Phusion will formulate and test products to exploit market opportunities within ProPhase's robust over-the-counter distribution channels.  For more information visit us at www.ProPhaseLabs.com.

Media Contact: Ilisa Wirgin / Jenny Miranda212-999-5585 iwirgin@5wpr.comjmiranda@5wpr.com   

SOURCE ProPhase Labs

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,968.80 -101.60 -0.56%
S&P 500 2,098.54 -15.95 -0.75%
NASDAQ 4,953.2880 -63.6410 -1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs